European Journal of Internal Medicine
Volume 20, Issue 4 , Pages 383-386 , July 2009

High levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions

  • Silvia Bielsa

      Affiliations

    • Pleural Diseases Unit, Department of Internal Medicine, Arnau de Vilanova University Hospital, Institut de Recerça Biomèdica de Lleida, Lleida, Spain
    • ,
  • Aureli Esquerda

      Affiliations

    • Department of Laboratory Medicine, Arnau de Vilanova University Hospital, Institut de Recerça Biomèdica de Lleida, Lleida, Spain
    • ,
  • Antonieta Salud

      Affiliations

    • Department of Medical Oncology, Arnau de Vilanova University Hospital, Institut de Recerça Biomèdica de Lleida, Lleida, Spain
    • ,
  • Ana Montes

      Affiliations

    • Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Vírgen del Rocio, Sevilla, Spain
    • ,
  • Elena Arellano

      Affiliations

    • Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Vírgen del Rocio, Sevilla, Spain
    • ,
  • Francisco Rodríguez-Panadero

      Affiliations

    • Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Vírgen del Rocio, Sevilla, Spain
    • ,
  • José M. Porcel

      Affiliations

    • Pleural Diseases Unit, Department of Internal Medicine, Arnau de Vilanova University Hospital, Institut de Recerça Biomèdica de Lleida, Lleida, Spain
    • Corresponding Author InformationCorresponding author. Department of Internal Medicine, University Hospital Arnau de Vilanova, Avda. Alcalde Rovira Roure 80, 25198 Lleida, Spain. Tel.: +34 973 248100x2431; fax: +34 973 248754.

Received 30 May 2008 ,Revised 31 October 2008 ,Accepted 16 November 2008.

References 

  1. Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J, Yang HB. Diagnostic accuracy of tumor markers for malignant pleural effusion: a meta-analysis. Thorax. 2008;63:35–41
  2. Duffy MJ. Role of tumor markers in patients with solid cancers: a critical review. Eur J Intern Med. 2007;18:175–184
  3. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. Clin Chem. 2001;47:624–630
  4. Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Phys. 2003;68:1075–1082
  5. Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni R, Grossi F, et al. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced non small cell lung cancer. Cancer. 2006;107:2842–2849
  6. Shering SG, Sherry F, McDermott EW, O'Higgins NJ, Duffy MJ. Preoperative CA15-3 concentrations predict outcome of patients with breast carcinoma. Cancer. 1998;83:2521–2527
  7. Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, et al. Management of malignant pleural effusions. Eur Respir J. 2001;18:402–419
  8. Bielsa S, Salud A, Martínez M, Esquerda A, Martín A, Rodríguez-Panadero F, et al. Prognostic significance of pleural fluid data in patients with malignant effusions. Eur J Intern Med. 2008;19:334–339
  9. Porcel JM, Vives M, Esquerda A, Salud A, Pérez B, Rodríguez-Panadero F. Use of panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3 and cytokeratin 19 fragments). Chest. 2004;126:1757–1763
  10. Tomita M, Shimizu T, Matsuzaki Y, Hara M, Ayabe T, Onitsuka T. Prognostic significance of carcinoembryonic antigen level in pleural lavage fluid for patients with lung adenocarcinoma. Ann Thorac Surg. 2005;80:276–281
  11. Galbis-Caravajal JM, Belloch-Carnión S, Sánchez-Payá J, Mafé-Madueño JJ, Baschwitz-Gómez B, Rodríguez-Paniagua JM. Prognostic value of the carcinoembryonic antigen found in pleural lavage fluid from patients with lung carcinoma. Arch Bronconeumol. 2005;41:185–188
  12. Ferrer J, Villarino MA, Encabo G, Felip E, Bermejo B, Vil S, et al. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA125, neuron-specific-enolase and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer. 1999;86:1488–1495
  13. Nicolini A, Tartarelli G, Carpi A, Metelli MR, Ferrari P, Anselmi L, et al. Intensive post-operative follow-up of breast cancer patients with tumor markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer. 2006;6:269
  14. Ghayumi SMA, Mehrabi S, Doroudchi M, Ghaderi A. Diagnostic value of tumor markers for differentiating malignant and benign pleural effusion of Iranian patients. Pathol Oncol Res. 2005;11:236–241
  15. Tampellini M, Berruti A, Gorzegno G, Bitossi R, Bottini A, Durando A, et al. Independent factors predict supranormal CA15-3 serum levels in advanced breast cancer patients at first disease relapse. Tumor Biol. 2001;22:367–373
  16. Lyubimova NV, Yag'ya TN, Chuchalin AG, Kushlinskii NE. Diagnostic value of tumor markers Cyfra 21-1 and neuron-specific enolase in analysis of pleural fluid. Bull Exp Biol Med. 2002;133:478–480
  17. Barlsi F, Gimenez C, Torre JP, Doddoli C, Mancini J, Greillier L, et al. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med. 2004;98:357–362
  18. Gary-Lee YC, Light RW. Management of malignant pleural effusions. Respirology. 2004;9:148–156
  19. Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusion. Chest. 2000;117:79–86

PII: S0953-6205(08)00320-8

doi: 10.1016/j.ejim.2008.11.009

European Journal of Internal Medicine
Volume 20, Issue 4 , Pages 383-386 , July 2009

Article Tools

* Image Usage & Resolution